FDA Approves First New Schizophrenia Drug in Decades

Cobenfy, a novel treatment targeting acetylcholine receptors, offers hope for millions with schizophrenia.

Cobenfy, developed by Bristol Myers Squibb, is the first new class of schizophrenia medication approved in over 70 years.
The drug targets acetylcholine receptors instead of dopamine, potentially benefiting patients unresponsive to current treatments.
Clinical trials showed significant improvement in schizophrenia symptoms with Cobenfy, though common side effects include nausea and indigestion.
Experts highlight Cobenfy's potential to address both positive and negative symptoms of schizophrenia with fewer side effects.
The medication is expected to be available in the U.S. by late October, with a monthly cost of $1,850 before insurance.